A*STAR Singapore Immunology Network (A*STAR SIgN)

Researchers engineer specialized T cells that can transiently and effectively attack liver cancer cells even in the presence of immunosuppressive drugs.

Maternal antibodies can cross the placenta and pass on mother’s allergies to her children in the womb.

Through the years, A*STAR has always stood at the forefront of science and technology and innovation. Here’s how A*STAR came to be and what it has in store in the upcoming decades.

Using single-cell sequencing technology, A*STAR scientists have identified a rare population of liver cells susceptible to damage from SARS-CoV-2 infections.

Unique immune responses shield some COVID-19 patients from the disease’s worst effects.

A newly-discovered role for an immune regulator in T cells may help unravel the molecular basis of inflammatory bowel disease and serve as a promising therapeutic target.

Data shows that antibodies produced as part of the COVID-19 immune response can neutralize a more transmissible variant of SARS-CoV-2.

Some neutralizing antibodies against SARS-CoV-2 may heighten lung tissue damage from COVID-19, an A*STAR study finds.

Live bacterial strains present in fetal tissues may help lay the cornerstones of early and potentially life-long immunity.

A scalable cell culture platform can generate universal red blood cells from stem cells, paving the way for manufacturing an abundant supply of blood for transfusions.

To see skin in its full, three-dimensional glory, it first needs to be transparent.

The amount of neutralizing antibodies produced by COVID-19 patients—and the length of time they remain detectable—can vary wildly, a study suggests.